Publikasi Scopus 2024 per tanggal 31 Januari 2024 (57 artikel)

Siagian S.N.; Christianto C.
Siagian, Sisca Natalia (57214134720); Christianto, Christianto (57564917700)
57214134720; 57564917700
A young woman with acute coronary syndrome and antiphospholipid syndrome. Is it the antiphospholipid syndrome or COVID-19 vaccination or classical risk as the risk factor? a case report
2024
Journal of Medical Case Reports
18
1
47
Pediatric Cardiology and Congenital Heart Disease Division, Department of Cardiology and Vascular Medicine, National Cardiovascular Center Harapan Kita, Universitas Indonesia, Jakarta, Indonesia; Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia
Siagian S.N., Pediatric Cardiology and Congenital Heart Disease Division, Department of Cardiology and Vascular Medicine, National Cardiovascular Center Harapan Kita, Universitas Indonesia, Jakarta, Indonesia; Christianto C., Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia
Background: Acute coronary syndrome (ACS) in young women is poorly understood due to underdiagnosis and undertreatment. One of the possible risk factors for ACS in young women is antiphospholipid syndrome (APS). Coronavirus disease 2019 (COVID-19) vaccination also emerged as one of the possible risk factors for ACS during the COVID-19 pandemic. Case presentation: Our patient, a 39-year-old Batak woman with dyslipidemia and family history of cardiovascular disease, experienced chest pain slightly improved at rest accompanied by autonomic symptoms. She was diagnosed with non-ST-elevation myocardial infarction (NSTEMI) based on her clinical features, dynamic electrocardiogram changes, troponin elevation, and multislice computed tomography angiography confirmed with diagnostic catheterization. The patient was managed by percutaneous coronary intervention with implantation of drug-eluting stents. On follow-up, the patient was diagnosed with APS based on history of preeclampsia with severe features in the first and third pregnancy, spontaneous abortion in the second pregnancy, history of transient ischemic attack, moderately positive lupus anticoagulant on two occasions with an interval of 12 weeks, and ACS. Further investigation revealed a history of COVID-19 vaccination with Sinovac four and six weeks before presentation. The patient was recommended for lifelong warfarin and short-term dual antiplatelet (aspirin and ticagrelor). Conclusions: Young women are not completely immune to ACS as evident in this case of ACS in a young woman with classical risk factors (dyslipidemia and family history of cardiovascular disease) and APS. Further studies are required to fill the knowledge gap on whether COVID-19 vaccination had any contribution to the ACS in the young woman. © 2024, The Author(s).
Acute coronary syndrome; Antiphospholipid syndrome; COVID-19 vaccination; Risk factor; Young women
Acute Coronary Syndrome; Adult; Antiphospholipid Syndrome; COVID-19; COVID-19 Vaccines; Dyslipidemias; Female; Humans; Pandemics; Risk Factors; acetylsalicylic acid; bisoprolol; clopidogrel; coronavac; drug eluting stent; enoxaparin; lansoprazole; lupus anticoagulant; noradrenalin; phospholipid antibody; rosuvastatin; sinovac; ticagrelor; troponin; warfarin; SARS-CoV-2 vaccine; acute coronary syndrome; adult; antiphospholipid syndrome; Article; Batak (people); case report; catheterization; clinical article; clinical feature; coronavirus disease 2019; disease severity; drug implantation; dyslipidemia; electrocardiogram; family history; female; follow up; human; medical history; multidetector computed tomography; non ST segment elevation myocardial infarction; percutaneous coronary intervent
Medicine Universitas Indonesia
We would like to thank those who have supported us in the making of this case report. We appreciate the grammatical and content suggestions and comments from dr. Miranda Rachellina. We are especially grateful to the Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, for their guidance and assistance in teaching the authors about research methodology and for
BioMed Central Ltd
17521947
38238833
Article
Q3
284
15666